|
|
|
| Effect of Pembrolizumab Combined with Chemotherapy on Advanced Intrahepatic Cholangiocarcinoma and Its Influence on Tumor Markers |
| DENG Jianhua, ZHAO Xinhua |
| First-author's address: Jiujiang NO.1 People's Hospital, Jiangxi Province, Jiujiang 332000, China |
|
|
|
|
Abstract Objective: To investigate the effect of Pembrolizumab combined with chemotherapy on advanced intrahepatic cholangiocarcinoma and its influence on tumor markers. Method: A total of 80 patients with advanced intrahepatic cholangiocarcinoma admitted to Jiujiang NO.1 People's Hospital from July 2021 to June 2022 were divided into a control group and an observation group according to the random number table method, 40 cases in each group. The control group was treated with routine chemotherapy, and the observation group was treated with Pembrolizumab combined with chemotherapy. The objective response rate, incidence of adverse reactions, before and after treatment of levels of apoptotic factors [X-linked inhibitor of apoptosis protein (XIAP) and second mitochondria-derived activator of caspases (Smac)] and tumor markers [carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA)] were compared between the two groups. Result: The objective response rate of the observation group was significantly higher than that of the control group, and the incidence of toxic side effects was significantly lower than that of the control group, the differences were statistically significant (P<0.05). There were no significant differences in the levels of apoptotic factors and tumor markers between the two groups before treatment (P>0.05). After 4 or 8 cycles of treatment, the Smac in the observation group were significantly higher than those in the control group, and the XIAP and tumor markers were significantly lower than those in the control group, the differences were statistically significant (P<0.05). Conclusion: Pembrolizumab combined with chemotherapy is effective in the treatment of advanced intrahepatic cholangiocarcinoma, which can control the level of tumor markers more effectively.
|
|
Received: 17 April 2023
|
|
|
|
|
|
|
